UnitedHealthcareMedium ImpactCoverage
Spevigo ® (Spesolimab-Sbzo)
Published June 2, 2026Effective June 1, 2026
AI Summary
UHC has updated their medical benefit drug policy for Spevigo (Spesolimab-Sbzo), a specialty medication used for treating generalized pustular psoriasis. This policy update affects coverage criteria, prior authorization requirements, or administration guidelines for this high-cost specialty drug.
Action Required
By June 1, 2026: Billing team must review updated Spevigo coverage criteria and prior authorization requirements. Update billing system with new policy guidelines for Spesolimab-Sbzo claims. Notify dermatology providers of any changes to administration or documentation requirements. Verify current prior auth processes align with updated policy to prevent claim denials.
Plan Types
Commercial
Specialties
dermatology